Halozyme Therapeutics | HALO - Capital Ordinaire





Capital Ordinaire Changement Date
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Alnylam Pharmaceuticals USD 133.44M 1.07M 2026-03
Amarin USD 20.81M 13K 2025-12
Amgen USD 540M 1000K 2026-03
Baxter International USD 516.45M 2.17M 2026-03
Cara Therapeutics USD 9.38M 9.38M 2025-09
Cytokinetics USD 124.43M 2.17M 2026-03
DBV Technologies USD 136.82M 51.98K 2025-09
Eli Lilly USD 943.5M 3.33M 2026-03
Esperion Therapeutics USD 245.22M 39.79M 2025-12
Halozyme Therapeutics USD 118.52M 741K 2026-03
Intrexon USD 0 0 2024-06
Ionis Pharmaceuticals USD 165.9M 3.93M 2026-03
MannKind USD 308.91M 1.07M 2026-03
Minerva Neurosciences USD 1000 0 2024-09
Nektar Therapeutics USD 20.38M 20.36M 2025-12
Pfizer USD 5.7B 13M 2026-03
Rigel Pharmaceuticals USD 17K 158K 2024-06
United Therapeutics USD 42.16M 1.49M 2026-03
Vanda Pharmaceuticals USD 58K 0 2024-12